Informations générales (source: ClinicalTrials.gov)
Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin
Observational
Hospices Civils de Lyon (Voir sur ClinicalTrials)
février 2019
septembre 2021
29 juin 2024
Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide,
concentration-dependent. Its spectrum concerns Gram-positive bacteria.
Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and
pulmonary eosinophilia associated with its use have been reported in Europe and
worldwide.
The purpose of this study is to describe the mechanism of occurrence of this AE with
dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a
role. Better understanding the mechanisms of appearance of this AE would provide
predictive elements making it possible to limit the occurrence of this AE in the future
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hospices Civils de Lyon - 69004 - Lyon - France | Eugenie Mabrut, CRA | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- patients having had an eosinophilic pneumonia under daptomycine given to treat an
osteoarticular infection (BJI/PJI)
- patients having had an eosinophilic pneumonia under daptomycine given to treat an
osteoarticular infection (BJI/PJI)
-